Conference abstract · 25 May 2017
Research articlePublished 2018
Voluminous and Vesicular: Diffuse Large B Cell Lymphoma (DLBCL)
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Previously chronicled as “Old histiocytic sarcoma” or “Old reticulum cell sarcoma”, Diffuse Large B Cell Lymphoma (DLBCL) is a composite and aggressive non-hodgkin’s lymphoma. An estimated 40% of lymphomas with multi-various disorders comprise the High-Grade B Cell Lymphoma (HGBCL). The mean age of detection may be at 60 years. Extra nodal and DLBCL comprise 40% instances with a half (50%) depicting progressive disease. The World Health Organization (WHO) categorization highlights the specific molecular attributes of the lymphoma such as the genomic rearrangements of the MYC and BCL2 and/or BCL6. Co-existent genetic anomalies may define the aggressive “Double Hit (DH) lymphoma” with a poor prognosis, initially scripted in 1988. DLBCL may emerge in the South Asian subcontinent with the prevalence identical to that of the developed world (30%-40%), though the incidence of the disorder may be enhanced in the Asian countries (60%-70%). The majority (>80%) of the individuals with an aggressive B Cell Double Hit Lymphoma (HGBCL DH) may elucidate concomitant translocations in the MYC and BCL2 genes. The remainder (20%) of the persons may depict concordant MYC and BCL6 translocations along with the enunciation of the BCL2 gene with an absence of the BCL2 translocation which may not influence the disease outcome. The Double Expresser Lymphomas (DE DLBCL), as exemplified by the co-existent MYC and BCL2, may depict a poor outcome, although superior to the “Double Hits (DHs)”. The DE DLBCL may be incorporated as the DLBCL Not Otherwise Specified (DLBCL NOS) by the WHO.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Review article · 8 Feb 2018
Competitive Treatment in Diffuse Large B-cell lymphoma (DLBCL) and the Future SOC for the First Line Therapy
Case report · 10 Apr 2024
Lacrimal Sac Diffuse Large B-Cell Lymphoma Presenting as Sudden Onset Binocular Diplopia: A Case Report
Commentary · 28 Jun 2023
Overcoming Immune Resistance in Diffuse Large B-Cell Lymphoma: Targeting Escape Mechanisms for Effective Immunotherapy
Research article · 2 May 2023
Demographic and overall survival pattern of diffuse large b-cell lymphoma in the university of Calabar teaching hospital, Calabar
More from this journal
The newest in Journal of Integrative Oncology.
Brief report · 28 Nov 2025
Integrative Oncology: Optimizing Cancer Care and Outcomes
Brief report · 28 Nov 2025
Biomarkers Predict Integrative Oncology Treatment Response
Opinion · 28 Nov 2025
Navigating Integrative Oncology Trial Design: Innovation and Ethics
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Integrative Oncology
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Anubha Bajaj”

